/

MYGN

Myriad Genetics, Inc.After hours

4.08−0.12 −2.86%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 4.08 0.00%

Open

4.20

Prev close

4.20

Day range

4.054.22

52-week range

2.748.59

Volume

1.38M0.67×

Mkt cap

390.25M

P/E ttm

—

Fwd P/E

-6.92

EPS ttm

-1.18

Div yield

0.00%

Earnings

Jul 30, 2026

From 52w high

−52.50%

Price Chart

Yahoo Finance · delayed

MYGNOct 13, 2026O 4.20H 4.22L 4.05C 4.08−0.12 (−2.86%)Vol 1.38M

SMA 503.61
SMA 2004.66

1Y change −45.60% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

MYGN Myriad Genetics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.67%
1 month: +19.30%
3 months: −32.45%
6 months: −16.90%
Year to date: −33.66%
1 year: −47.96%

Valuation & ownership

Market cap: 390.25M
Enterprise value: 497.03M
P/E (ttm): —
Forward P/E: -6.92
PEG ratio: 1.24
Price / book: 1.28
Price / sales (ttm): 0.48
EV / EBITDA: -12.33
EPS (ttm): -1.18
EPS (forward): -0.5898
Beta (5y monthly): 1.64
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 95.65M
Float: 79.29M
Short % of float: 9.16%
Short ratio (days): 4.09
Held by insiders: 4.01%
Held by institutions: 97.11%
Avg volume (3m): 2.06M
50-day average: 3.59
200-day average: 4.68
52-week change: −47.96%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 50.9
vs 50-day SMA: +13.14%
vs 200-day SMA: −12.52%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.25%
Realised vol (20d, ann.): 67.7%
From 52-week high: −52.50%
From 52-week low: +48.91%

ANR

Analyst Consensus

8 analysts

Consensus

Hold

3.22 on a 1 (strong buy) – 5 (sell) scale

Mean target

4.11

+0.80% implied

Low 2.00Median 3.85High 8.00

Recommendation trend

Now1 / 5 / 3
1m ago

DES

About Myriad Genetics, Inc.

Yahoo Finance profile

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile, a genomic profiling test; Prequel Prenatal Screen, a prenatal screening test to screen chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess risk of passing on recessive genetic condition to offspring; SneakPeek Early Gender DNA, a non-invasive blood test that predicts the fetus's gender; FirstGene; and GeneSight Psychotropic Mental Health Medication, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company has a strategic alliance with SOPHiA GENETICS SA to advance new prostate cancer-specific genomic instability score technology for oncology approaches with AstraZeneca. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Sector: Healthcare
Industry: Diagnostics & Research
Employees: 2,700

SEAS

Seasonality · MYGN

2007–2026 · monthly returns

Strongest month Jan +6.24%Weakest month Dec −3.00%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-8.6	-18.0	-2.4	5.6	-16.4	43.8	-49.9	12.6	33.9	-5.3			−33.7%
2025	-7.6	-15.3	-17.3	-16.5	-43.5	26.7	-27.7	65.9	13.5	11.2	-5.1	-19.4	−55.1%
2024	11.8	-2.2	1.9	-8.2	16.3	7.5	14.3	1.3	-3.3	-19.8	-25.9	-15.7	−28.4%
2023	35.9	-4.1	22.8	-8.4	3.6	5.1	-3.6	-20.1	-10.1	-2.9	22.5	0.3	+31.9%
2022	-4.7	-7.3	3.4	-18.7	-6.1	-5.6	45.2	-15.3	-14.6	8.7	-2.3	-28.4	−47.4%
2021	39.4	10.7	-0.1	-0.8	-5.2	6.7	3.4	13.1	-9.8	-4.7	-16.0	6.7	+39.6%
2020	1.5	-36.3	-18.8	8.0	-6.0	-22.0	6.4	10.8	-2.5	-4.7	41.1	12.7	−27.4%
2019	-3.0	10.1	7.0	-5.2	-21.3	12.2	4.9	-19.3	21.7	17.6	-23.6	5.8	−6.3%
2018	7.4	-12.1	-8.9	-4.3	29.1	2.4	17.1	13.8	-7.6	-2.1	-28.4	-9.8	−15.4%
2017	-2.9	20.1	-1.2	-4.2	10.7	27.0	-6.1	25.6	18.7	-5.3	1.0	-0.8	+106.1%
2016	-9.7	-10.2	6.9	-3.8	-5.9	-9.7	1.2	-34.3	1.1	-4.2	-15.3	-0.1	−61.4%
2015	9.9	-9.0	3.9	-6.7	2.8	0.1	0.4	10.1	-0.2	7.7	7.8	-0.8	+26.7%
2014	31.7	31.1	-5.6	23.5	-21.4	17.4	-7.2	0.2	6.6	2.4	-15.1	1.6	+62.3%
2013	-0.7	-6.1	-0.0	9.6	15.3	-16.3	10.4	-11.8	-10.2	3.8	22.0	-29.5	−23.0%
2012	13.0	2.3	-2.2	9.9	-7.2	-1.5	4.5	0.6	7.8	-2.9	9.7	-5.1	+30.1%
2011	-12.6	-7.2	8.8	6.4	18.5	-10.6	-6.3	-6.8	-5.5	13.6	-0.1	-1.5	−8.3%
2010	-9.9	-2.1	4.6	-0.2	-24.0	-18.1	-2.9	7.7	5.0	21.0	8.4	6.1	−12.5%
2009	12.5	5.7	15.3	-14.7	-6.8	-1.4	-23.1	11.5	-10.3	-11.4	-4.8	12.8	−21.2%
2008	-7.3	-13.9	8.8	3.1	16.6	-6.0	46.1	2.6	-4.9	-2.8	-6.0	11.8	+42.7%
2007	14.2	-6.4	3.0	6.1	4.2	-2.3	0.5	17.6	18.6	6.2	-12.9	-3.7	+48.3%

INSD

Insider Activity · MYGN

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

1.00M shares

Sells, 6 months

15K shares

Net shares

+988.3K

Net change in insider shares

+34.80%

Date	Insider	Transaction	Shares	Value
Sep 15, 2026	Sikri VishalOfficer	Stock Award(Grant) at price 0.00 per share.	257.7K	—
Jun 10, 2026	Donnelly Brian JOfficer	Stock Award(Grant) at price 3.94 per share.	5K	$19.68K
Jun 10, 2026	Raha Samraat S.Chief Executive Officer	Stock Award(Grant) at price 3.94 per share.	3.5K	$13.94K
Jun 7, 2026	Kumar RashmiDirector	Sale at price 4.46 per share.	15K	$66.84K
Jun 3, 2026	Davis Mark StevenDirector	Stock Award(Grant) at price 0.00 per share.	59.7K	—
Jun 3, 2026	Phanstiel S LouiseDirector	Stock Award(Grant) at price 0.00 per share.	59.7K	—
Jun 3, 2026	Dreismann HeinrichDirector	Stock Award(Grant) at price 0.00 per share.	59.7K	—
Jun 3, 2026	Bisaro Paul M.Director	Stock Award(Grant) at price 0.00 per share.	59.7K	—
Jun 3, 2026	Skovronsky DanielDirector	Stock Award(Grant) at price 0.00 per share.	59.7K	—
Jun 3, 2026	Reitan Colleen F.Director	Stock Award(Grant) at price 0.00 per share.	59.7K	—
Jun 3, 2026	Newcomer Lee NisleyDirector	Stock Award(Grant) at price 0.00 per share.	59.7K	—
Jun 3, 2026	Kumar RashmiDirector	Stock Award(Grant) at price 0.00 per share.	59.7K	—
May 31, 2026	Jampa RajChief Technology Officer	Stock Award(Grant) at price 0.00 per share.	251.9K	—
May 13, 2026	Bisaro Paul M.Director	Purchase at price 3.68 per share.	7.5K	$27.64K
Mar 11, 2026	Fox Jennifer LynneOfficer	Stock Award(Grant) at price 0.00 per share.	195.9K	—
Mar 11, 2026	Muzzey DaleOfficer	Stock Award(Grant) at price 0.00 per share.	173.2K	—
Mar 11, 2026	Donnelly Brian JOfficer	Stock Award(Grant) at price 0.00 per share.	226.8K	—
Mar 11, 2026	Wheeler Benjamin RichardChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	206.2K	—
Mar 11, 2026	Solaiman ShereenOfficer	Stock Award(Grant) at price 0.00 per share.	173.2K	—
Mar 11, 2026	Verratti Mark SChief Operating Officer	Stock Award(Grant) at price 0.00 per share.	247.4K	—

MYGN

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

MYGN

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Myriad Genetics, Inc.

Seasonality · MYGN

Insider Activity · MYGN

Congress Trades · MYGN

Investors Holding MYGN

Investors Holding MYGN

Congress Trades · MYGN

Insider Activity · MYGN

Seasonality · MYGN

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Myriad Genetics, Inc.

Financial Snapshot

Earnings & Dividends

News